SironRX Therapeutics, Inc., a Cleveland, OH-based company that is developing a topical therapy to enhance healing of and decrease scar formation in wounds, has received a $500,000 investment from JumpStart Ventures and Cleveland Clinic.
The company intends to use the funding, which is part of a larger fundraising round, to begin a Phase II clinical trial evaluating the potential of its lead product, JVS-100, a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1), which is designed to promote wound repair and prevent scarring in post-surgical wounds.
Pre-clinical studies have demonstrated that there may be broader dermal applications for JVS-100, including treatment of chronic ulcers and burns.
SironRX is a spinoff of the privately-held biotechnology company Juventas Therapeutics, which licensed the drug’s intellectual property from Cleveland Clinic in 2007.
In connection with the funding, Michael Lang, a JumpStart Venture Partner, will now be working with SironRX. CSO of the company is Marc Penn, M.D., Ph.D., Director of the Skirball Cardiovascular Cell Therapy Laboratory at Cleveland Clinic.